JPRN-jRCTs031190151招募中未知
The relationship of AMPA receptor density with presence or absence of subsequent onset in high-risk cases of psychosis: A longitudinal PET study using [11C] K-2
Eiro Tsuyoshi0 个研究点目标入组 30 人开始时间: 2019年12月2日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 < 40age old（—）
- 性别
- All
入选标准
- •We will target cases that meet all the following conditions.
- •1 High risk cases of psychosis that meet criteria using SIPS (Structured Interview for Prodrome Syndromes) / SOPS (The Scale of Prodromism Symptoms)
- •2 Men and women between 16 and 40 years old at registration
- •3 Patients over 20 years of age who gave written informed consent to participate in this study; under 20 years of age, informed consent was obtained for involved in this research from himself / her parents Case
- •4 Patients in which the patient's consent judgment ability is judged to be sufficient by the evaluation by the MacArthur Competence Assessment Tool (MacCAT)
排除标准
- •It will be excluded if any of the following conditions apply.
- •1 During pregnancy, nursing or wishing to be pregnant(For premenopausal women,blood hCG is measured by blood sampling and confirmed to be less than 6 mIU / ml)
- •2 Sensitive to alcohol
- •3 Combination of serious neurologic diseases (neurodegenerative diseases, cases of cerebral hemorrhage and cerebral infarction which are not slight in the image before this study participation)
- •4 History of epilepsy
- •5 Take Perranpanel, Topiramate, antipsychotic medication within 4 weeks before registration
- •6 Substance-related disorders within 6 months (except for nicotine and caffeine)
- •7 Dependent substances positive by urine screening (except those who are positive for the medicine being taken for treatment)
- •8 Implantation of metal substances and pacemakers
- •9 head, neck and body size not suitable for MRI scanner
- •10 A tattoo larger than one point (including tattoo and art makeup)
- •11 Advanced claustrophobic
- •12 A remarkable variant of brain structure (including congenital and traumatic)
- •13 At the time of registration, any of the following laboratory test value abnormalities
- •Serum creatinine 1.5 mg / dl or more
- •AST 150 IU / L or more
- •ALT 150 IU / L or more
- •14 Participating in unapproved nuclear medicine clinical trials and clinical trials within 6 months prior to enrollment
- •15 Participating in other trials or clinical trials within 12 weeks prior to enrollment (limited to those with invasiveness / intervention)
- •16 Patients judged as inappropriate for study by the research investigator
研究者
相似试验
已完成
不适用
A clinical trial to examine the distribution of [11C]K-2 in patients with schizophreniaSchizophreniaJPRN-jRCTs031190197Miyazaki Tomoyuki30
已完成
不适用
A clinical trial to examine the distribution of [11C]K-2 in patients with depression and bipolar disorder.Patients with depression,bipolar disorderJPRN-jRCTs031190150Miyazaki Tomoyuki60
已完成
不适用
A clinical trial to examine the distribution of [11C]K-2 in patients with autism spectrum disorder.Autism spectrum disorderJPRN-jRCTs031190149Miyazaki Tomoyuki30
已完成
不适用
Measurement of AMPA receptor density in patients with depression and bipolar disorder: a PET studybipolar disorderDepressionJPRN-UMIN000039357Department of Physiology,Yokohama City University, School of Medicie60
已完成
不适用
Measurement of AMPA receptor density in patients with schizophrenia: a PET studySchizophreniaJPRN-UMIN000039356Department of Physiology,Yokohama City University, School of Medicie30